Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Aug 1;100(3):613–619. doi: 10.1172/JCI119572

Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

L Ziporen 1, Y Shoenfeld 1, Y Levy 1, A D Korczyn 1
PMCID: PMC508229  PMID: 9239409

Abstract

Antiphospholipid antibodies (aPL) have been associated with various neurological manifestations, but the underlying mechanism has not been elucidated. We assessed mice with induced experimental antiphospholipid syndrome (APS) for neurological and behavioral changes. After immunization with monoclonal human anticardiolipin antibody (H-3), female BALB/c mice developed elevated levels of circulating anti-negatively charged phospholipids (aPL), anti-beta2-glycoprotein I (abeta2GPI), and anti-endothelial cell antibodies (AECA), along with clinical manifestations of APS like thrombocytopenia and fetus resorption. APS mice were impaired neurologically and performed several reflexes less accurately compared to the controls, including placing reflex (P < 0.05), postural reflex (P < 0.05), and grip test (P = 0.05). The APS mice also exhibited hyperactive behavior in an open field, which tests spatial behavior (P < 0.03), and displayed impaired motor coordination on a rotating bar. aPL in combination with abeta2GPI and AECA is probably involved in the neurological and behavioral defects shown in mice with experimental APS.

Full Text

The Full Text of this article is available as a PDF (204.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D., Delezé M., Oria C. V., Sánchez-Guerrero J., Gómez-Pacheco L., Cabiedes J., Fernández L., Ponce de León S. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989 Nov;68(6):353–365. doi: 10.1097/00005792-198911000-00003. [DOI] [PubMed] [Google Scholar]
  2. Asherson R. A., Mercey D., Phillips G., Sheehan N., Gharavi A. E., Harris E. N., Hughes G. R. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987 Aug;46(8):605–611. doi: 10.1136/ard.46.8.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest. 1992 May;89(5):1558–1563. doi: 10.1172/JCI115749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blank M., Cohen J., Toder V., Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3069–3073. doi: 10.1073/pnas.88.8.3069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brey R. L., Cote S., Barohn R., Jackson C., Crawley R., Teale J. M. Model for the neuromuscular complications of systemic lupus erythematosus. Lupus. 1995 Jun;4(3):209–212. doi: 10.1177/096120339500400308. [DOI] [PubMed] [Google Scholar]
  6. Brey R. L., Gharavi A. E., Lockshin M. D. Neurologic complications of antiphospholipid antibodies. Rheum Dis Clin North Am. 1993 Nov;19(4):833–850. [PubMed] [Google Scholar]
  7. Cabiedes J., Cabral A. R., Alarcón-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol. 1995 Oct;22(10):1899–1906. [PubMed] [Google Scholar]
  8. Damianovich M., Gilburd B., George J., Del Papa N., Afek A., Goldberg I., Kopolovic Y., Roth D., Barkai G., Meroni P. L. Pathogenic role of anti-endothelial cell antibodies in vasculitis. An idiotypic experimental model. J Immunol. 1996 Jun 15;156(12):4946–4951. [PubMed] [Google Scholar]
  9. Dar M. S., Wooles W. R. Effect of chronically administered methylxanthines on ethanol-induced motor incoordination in mice. Life Sci. 1986 Oct 20;39(16):1429–1437. doi: 10.1016/0024-3205(86)90547-3. [DOI] [PubMed] [Google Scholar]
  10. Del Papa N., Guidali L., Spatola L., Bonara P., Borghi M. O., Tincani A., Balestrieri G., Meroni P. L. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995 Mar-Apr;13(2):179–185. [PubMed] [Google Scholar]
  11. Digre K. B., Durcan F. J., Branch D. W., Jacobson D. M., Varner M. W., Baringer J. R. Amaurosis fugax associated with antiphospholipid antibodies. Ann Neurol. 1989 Mar;25(3):228–232. doi: 10.1002/ana.410250304. [DOI] [PubMed] [Google Scholar]
  12. Drenkard C., Sánchez-Guerrero J., Alarcón-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol. 1989 May;16(5):614–617. [PubMed] [Google Scholar]
  13. Eilam D., Golani I. Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behav Brain Res. 1989 Sep 1;34(3):199–211. doi: 10.1016/s0166-4328(89)80102-0. [DOI] [PubMed] [Google Scholar]
  14. Eilam D., Szechtman H., Faigon M., Dubovik V., Feldon J., Michaelson D. M. Disintegration of the spatial organization of behavior in experimental autoimmune dementia. Neuroscience. 1993 Sep;56(1):83–91. doi: 10.1016/0306-4522(93)90564-v. [DOI] [PubMed] [Google Scholar]
  15. Furie R., Ishikawa T., Dhawan V., Eidelberg D. Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal hypermetabolism. Neurology. 1994 Nov;44(11):2197–2199. doi: 10.1212/wnl.44.11.2197. [DOI] [PubMed] [Google Scholar]
  16. Galli M., Comfurius P., Maassen C., Hemker H. C., de Baets M. H., van Breda-Vriesman P. J., Barbui T., Zwaal R. F., Bevers E. M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990 Jun 30;335(8705):1544–1547. doi: 10.1016/0140-6736(90)91374-j. [DOI] [PubMed] [Google Scholar]
  17. Garlanda C., Parravicini C., Sironi M., De Rossi M., Wainstok de Calmanovici R., Carozzi F., Bussolino F., Colotta F., Mantovani A., Vecchi A. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7291–7295. doi: 10.1073/pnas.91.15.7291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gilburd B., Stein M., Tomer Y., Tanne D., Abramski O., Chapman Y., Ahiron A., Blank M., Shoenfeld Y. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome: cross-reactive or pathogenic? Autoimmunity. 1993;16(1):23–27. doi: 10.3109/08916939309010644. [DOI] [PubMed] [Google Scholar]
  19. Ginsburg K. S., Liang M. H., Newcomer L., Goldhaber S. Z., Schur P. H., Hennekens C. H., Stampfer M. J. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992 Dec 15;117(12):997–1002. doi: 10.7326/0003-4819-117-12-997. [DOI] [PubMed] [Google Scholar]
  20. Harris E. N., Gharavi A. E., Asherson R. A., Boey M. L., Hughes G. R. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol. 1984 Jan-Mar;2(1):47–51. [PubMed] [Google Scholar]
  21. Hashimoto Y., Kawamura M., Ichikawa K., Suzuki T., Sumida T., Yoshida S., Matsuura E., Ikehara S., Koike T. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol. 1992 Aug 1;149(3):1063–1068. [PubMed] [Google Scholar]
  22. Herranz M. T., Rivier G., Khamashta M. A., Blaser K. U., Hughes G. R. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 1994 Apr;37(4):568–571. doi: 10.1002/art.1780370418. [DOI] [PubMed] [Google Scholar]
  23. Hess D. C., Sheppard J. C., Adams R. J. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke. 1993 Jul;24(7):994–999. doi: 10.1161/01.str.24.7.994. [DOI] [PubMed] [Google Scholar]
  24. Hess D. C., Taormina M., Thompson J., Sethi K. D., Diamond B., Rao R., Chamberlain C. R., Feldman D. S. Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol. 1993 Apr;20(4):610–617. [PubMed] [Google Scholar]
  25. Hojnik M., George J., Ziporen L., Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996 Apr 15;93(8):1579–1587. doi: 10.1161/01.cir.93.8.1579. [DOI] [PubMed] [Google Scholar]
  26. Hughes G. R. The antiphospholipid syndrome: ten years on. Lancet. 1993 Aug 7;342(8867):341–344. doi: 10.1016/0140-6736(93)91477-4. [DOI] [PubMed] [Google Scholar]
  27. Husby G., van de Rijn I., Zabriskie J. B., Abdin Z. H., Williams R. C., Jr Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med. 1976 Oct 1;144(4):1094–1110. doi: 10.1084/jem.144.4.1094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Inzelberg R., Korczyn A. D. Lupus anticoagulant and late onset seizures. Acta Neurol Scand. 1989 Feb;79(2):114–118. doi: 10.1111/j.1600-0404.1989.tb03721.x. [DOI] [PubMed] [Google Scholar]
  29. Khamashta M. A., Gil A., Anciones B., Lavilla P., Valencia M. E., Pintado V., Vázquez J. J. Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1988 Aug;47(8):681–683. doi: 10.1136/ard.47.8.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol. 1994 Aug 1;153(3):1328–1332. [PubMed] [Google Scholar]
  31. Lavalle C., Pizarro S., Drenkard C., Sánchez-Guerrero J., Alarcón-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol. 1990 Jan;17(1):34–37. [PubMed] [Google Scholar]
  32. Levine S. R., Deegan M. J., Futrell N., Welch K. M. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990 Aug;40(8):1181–1189. doi: 10.1212/wnl.40.8.1181. [DOI] [PubMed] [Google Scholar]
  33. McCrae K. R., DeMichele A., Samuels P., Roth D., Kuo A., Meng Q. H., Rauch J., Cines D. B. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol. 1991 Dec;79(4):595–605. doi: 10.1111/j.1365-2141.1991.tb08087.x. [DOI] [PubMed] [Google Scholar]
  34. Montalbán J., Cervera R., Font J., Ordi J., Vianna J., Haga H. J., Tintoré M., Khamashta M. A., Hughes G. R. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology. 1992 Mar;42(3 Pt 1):681–682. doi: 10.1212/wnl.42.3.681. [DOI] [PubMed] [Google Scholar]
  35. Pierangeli S. S., Barker J. H., Stikovac D., Ackerman D., Anderson G., Barquinero J., Acland R., Harris E. N. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994 May;71(5):670–674. [PubMed] [Google Scholar]
  36. Robbins L. Migraine and anticardiolipin antibodies--case reports of 13 patients, and the prevalence of antiphospholipid antibodies in migraineurs. Headache. 1991 Sep;31(8):537–539. doi: 10.1111/j.1526-4610.1991.hed3108537.x. [DOI] [PubMed] [Google Scholar]
  37. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J. 1994 Dec;8(15):1296–1301. doi: 10.1096/fasebj.8.15.8001742. [DOI] [PubMed] [Google Scholar]
  38. Silver R. K., Mullen T. A., Caplan M. S., O'Connell P. D., Ragin A. Inducible platelet adherence to human umbilical vein endothelium by anticardiolipin antibody-positive sera. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):702–707. doi: 10.1016/0002-9378(95)90326-7. [DOI] [PubMed] [Google Scholar]
  39. Smith H. R., Hansen C. L., Rose R., Canoso R. T. Autoimmune MRL-1 pr/1pr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol. 1990 Jul;17(7):911–915. [PubMed] [Google Scholar]
  40. Sun K. H., Liu W. T., Tsai C. Y., Liao T. S., Lin W. M., Yu C. L. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis. 1992 Jun;51(6):707–712. doi: 10.1136/ard.51.6.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sutjita M., Hohmann A., Comacchio R., Bradley J. Polyspecific human and murine antibodies to diphtheria and tetanus toxoids and phospholipids. Clin Exp Immunol. 1988 Aug;73(2):191–197. [PMC free article] [PubMed] [Google Scholar]
  42. Toubi E., Khamashta M. A., Panarra A., Hughes G. R. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med. 1995 Oct;99(4):397–401. doi: 10.1016/s0002-9343(99)80188-0. [DOI] [PubMed] [Google Scholar]
  43. Tupper D. E., Wallace R. B. Utility of the neurological examination in rats. Acta Neurobiol Exp (Wars) 1980;40(6):999–1003. [PubMed] [Google Scholar]
  44. Westerman E. M., Miles J. M., Backonja M., Sundstrom W. R. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis Rheum. 1992 Sep;35(9):1038–1041. doi: 10.1002/art.1780350908. [DOI] [PubMed] [Google Scholar]
  45. Ziporen L., Goldberg I., Arad M., Hojnik M., Ordi-Ros J., Afek A., Blank M., Sandbank Y., Vilardell-Tarres M., de Torres I. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996 Jun;5(3):196–205. doi: 10.1177/096120339600500306. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES